BioLynx
Hangzhou
About BioLynx
BioLynx is a patented recombinant monoclonal antibody technology. Their services include antigen preparation, animal immunization, PBMC collection, B+ cell isolation, B+ cell culture, antibody validation, transfection, IgG expression, IgG DNA cloning, and immunoassays.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Funding stage: Early Stage Venture
- Last round: Series A (Apr 2018)
- Website: biolynx.cn
Industries & Categories
Health Diagnostics
Canonical: https://fsome.com/organization/biolynx-3175183 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.